<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230318</url>
  </required_header>
  <id_info>
    <org_study_id>DZB-CS-301</org_study_id>
    <secondary_id>ARQ 087-301</secondary_id>
    <nct_id>NCT03230318</nct_id>
  </id_info>
  <brief_title>Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma</brief_title>
  <acronym>FIDES-01</acronym>
  <official_title>A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of
      derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1
      in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors
      harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene
      mutations or amplifications (based on NGS testing performed or commissioned by the respective
      study center) and who received at least one prior regimen of systemic therapy. Subjects will
      be dosed orally once per day at 300 mg of derazantinib capsules.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Substudy 1: Anti-cancer activity of derazantinib by Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>ORR will be assessed by central radiology review as per RECIST version 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 2: Anti-tumor activity of derazantinib by Progression Fress Survival at 3 months (PFS 3)</measure>
    <time_frame>3 months</time_frame>
    <description>PFS 3 will be assessed based on survival status or central radiology review (Response Evaluation Criteria in Solid Tumors, RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of derazantinib as assessed by adverse events</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
    <description>Adverse events will be graded using NCI CTCAE guidelines, version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-cancer activity of derazantinib by duration of response (DoR)</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>DoR will be assessed by central radiology review per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-cancer activity of derazantinib by progression free survival (PFS)</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>PFS will be assessed by central radiology review per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-cancer activity of derazantinib by overall survival (OS)</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
    <description>OS will be calculated from the first date of receiving study drug until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life as assessed by the EORTC QLQ-BIL21 questionnaire</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life as assessed by the EuroQol EQ-5D questionnaire</measure>
    <time_frame>Up to approximately 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 2: Anti-cancer activity of derazantinib by Objective Response Rate</measure>
    <time_frame>Up to approximately 32 weeks</time_frame>
    <description>ORR will be assessed by central radiology review as per RECIST version 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <condition>Combined Hepatocellular and Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>derazantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>derazantinib</intervention_name>
    <description>derazantinib will be orally administered at 300 mg once per day one hour prior to or two hours after a meal and is supplied as 100 mg capsules.</description>
    <arm_group_label>derazantinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent granted prior to initiation of any study-specific
             procedures

          2. 18 years of age or older

          3. Histologically or cytologically confirmed locally advanced, inoperable (where surgery
             is not indicated due to disease extension, co-morbidities, or other technical
             reasons), or metastatic iCCA or mixed histology tumors (combined
             hepatocellular-cholangiocarcinoma [cHCC-CCA])

          4. Substudy 1: FGFR2 gene fusion status based on the following assessments:

               1. If central laboratory designated by Sponsor:

                  Positive FISH test; and/or

               2. If non-central laboratory:

             i) Positive FISH or NGS test: patients may be enrolled and may start dosing, but
             central confirmation is required* ii) Negative FISH or NGS test: tissue may be
             submitted to the central laboratory designated by the Sponsor, and patients may only
             be enrolled if the central test is positive

             *Using standard protocols and approved by local IRB/EC, by CLIA or other similar
             agency.

             Substudy 2: FGFR2 mutation status based on local NGS testing performed or commissioned
             by the respective study site using a validated test. For NGS testing, no central
             laboratory will be established for the purpose of Substudy 2.

          5. Received at least one regimen of prior systemic therapy and then experienced
             documented radiographic progression

          6. Measurable disease by RECIST version 1.1 criteria

          7. ECOG performance status ≤ 1

          8. Adequate organ functions as indicated by the following laboratory values (based on
             screening visit values from the central laboratory).

               -  Hematological

                    -  Hemoglobin (Hgb) ≥ 9.0 g/dL

                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

                    -  Platelet count ≥ 75 x 109/L

                    -  International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤
                       3 for subjects receiving anticoagulant therapy such as Coumadin or heparin

               -  Hepatic

                    -  Total bilirubin ≤ 2 x ULN

                    -  AST and ALT ≤ 3 ULN (≤ 5 x ULN for subjects with liver metastases)

                    -  Albumin ≥ 2.8 g/dL

               -  Renal

                    -  Serum creatinine ≤ 1.5 x ULN

                    -  Creatinine clearance of ≥ 60 mL/min as estimated by the Cockcroft-Gault
                       equation

          9. Female and male patients of child-producing potential must agree to avoid becoming
             pregnant or impregnating a partner, respectively, use double-barrier contraceptive
             measures, oral contraception, or avoidance of intercourse, during the study*, and
             until at least 120 for 90 days after the last dose of derazantinib.

             *From the day of first study medication, or for oral contraception from 14 days before
             first study medication.

             Male patients are considered not to be of child-producing potential if they have
             azoospermia (whether due to vasectomy or an underlying medical condition). Female
             patients are considered not to be of child-producing potential if they are:

               -  postmenopausal* , or

               -  have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or
                  bilateral tubal ligation/occlusion, at least 6 weeks prior to screening, or

               -  have a congenital or acquired condition that prevents childbearing.

             Male or female patients of child-producing potential must agree to comply with one of
             the following until at least 120 days after the last dose of derazantinib:

               1. Abstinence from heterosexual activity**

               2. Using (or having their partner use) an acceptable method of contraception during
                  heterosexual activity. Acceptable methods of contraception are***:

                    -  any ONE of:

                       - an intrauterine device (IUD)

                       - vasectomy of a female patient's male partner

                       - a contraceptive rod implanted into the skin.

                    -  any TWO in combination of:

                       - diaphragm with spermicide (cannot be used in conjunction with cervical
                       cap/spermicide)

                       - cervical cap with spermicide (nulliparous women only)

                       - contraceptive sponge (nulliparous women only)

                       - male condom or female condom (cannot be used together)

                         -  hormonal contraceptive (oral contraceptive pill [estrogen/progestin
                            pill or progestin-only pill], contraceptive skin patch, vaginal
                            contraceptive ring, or subcutaneous contraceptive injection)

                            *Postmenopausal is defined as at least 12 months with no menses without
                            an alternative medical cause; in women &lt; 45 years of age a high
                            follicle stimulating hormone (FSH) level in the postmenopausal range
                            may be used to confirm a post -menopausal state in women not using
                            hormonal contraception or hormonal replacement therapy. In the absence
                            of 12 months of amenorrhea, a single FSH measurement is not sufficient.

                            **Abstinence (relative to heterosexual activity) can be used as the
                            sole method of contraception if it is consistently employed as the
                            subject's preferred and usual lifestyle and if considered acceptable by
                            local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g.,
                            calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and
                            withdrawal are not acceptable methods of contraception.

                              -  If a contraceptive method listed above is restricted by local
                                 regulations/guidelines, then it does not qualify as an acceptable
                                 method of contraception for subjects participating at sites in
                                 this country/region.

             Exclusion Criteria:

          1. Systemic anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted
             therapy, or investigational agents within four weeks of the first dose of
             derazantinib, or within five half-lives of any investigational or licensed medicinal
             product, whichever is the longer period.

          2. Major surgery, locoregional therapy, or radiation therapy within four weeks of the
             first dose of derazantinib

          3. Previous treatment with any FGFR inhibitor (e.g., ponatinib, dovitinib, nintedanib,
             AZD4547, NVP-BGJ398, LY2784455, BAY1163877)

             - Subjects who received less than four weeks of therapy and were unable to continue
             therapy due to toxicity will be allowed to participate

          4. Unable or unwilling to swallow the complete daily dose of derazantinib capsules

          5. Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects
             must have stable disease ≥ 3 months, confirmed by magnetic resonance imaging (MRI) or
             computed tomography (CT) scan, and/or have CNS metastases well controlled by low-dose
             steroids, anti-epileptics, or other symptom-relieving medications)

          6. Current evidence of corneal or retinal disorder, including but not limited to
             bullous/band keratopathy, keratoconjunctivitis, corneal abrasion,
             inflammation/ulceration, confirmed by ophthalmologic examination

          7. Concurrent uncontrolled or active hepatobiliary disorders, untreated or ongoing
             complications after laparoscopic procedures or stent placement, including but not
             limited to active cholangitis, biloma or abscess (to be eligible, the subjects have to
             be treated and disorders/complications should be resolved within 2 weeks prior to the
             first dose of derazantinib)

          8. History of significant cardiac disorders:

             - Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per
             the New York Heart Association (NYHA) classification within 6 months of the first dose
             of derazantinib (MI that occurred &gt; 6 months prior to the first dose of derazantinib
             will be permitted)

             - QTcF &gt;450 msec (males or females)

          9. Serum electrolyte abnormalities defined as follows:

             - Hyperphosphataemia: Serum phosphate &gt; institutional ULN

             - Hyperkalemia: &gt; 6.0 mmol/L

             - Hypokalemia: &lt; 3.0 mmol/L

             - Hypercalcemia: corrected serum calcium &lt; 1.75 mmol/L (&lt; 7.0 mg/dL)

               -  Hypocalcemia: corrected serum calcium &gt; 3.1 mmol/L (&gt; 12.5 mg/dL)

               -  Hypomagnesemia: &lt; 0.4 mmol/L (&lt; 0.9 mg/dL)

         10. Significant gastrointestinal disorder(s) that could, in the opinion of the
             Investigator, interfere with the absorption, metabolism, or excretion of derazantinib
             (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)

         11. Previous malignancy within 2 years of the first dose of derazantinib, except
             curatively treated or low grade malignancies such as non-melanoma skin cancer,
             carcinoma in-situ of the breast, cervix, and superficial bladder tumors

         12. Concurrent uncontrolled illness not related to cancer, including but not limited to:

               -  Psychiatric illness/substance abuse/social situation that would limit compliance
                  with study requirements

               -  Known uncontrolled human immunodeficiency virus (HIV) infection

         13. Blood or albumin transfusion within 5 days of the blood draw being used to confirm
             eligibility

         14. Pregnant or breast feeding

         15. Known hypsersensitivity to derazantinib, or to any of the study drug excipients
             (starch, lactose, crospovidone, magnesium stearate)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Braun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Braun, MD</last_name>
    <phone>+41 61 606 12 25</phone>
    <email>stephan.braun@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédérique Cantero, MD</last_name>
    <phone>+41 61 606 1329</phone>
    <email>frederique.cantero@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Escobar, Study Coordinator</last_name>
      <email>alicia.m.escobar@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6800</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Demols, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Axelle Ghilain, Study Coordinator</last_name>
      <phone>+32 2 555 44 55</phone>
      <email>axelle.ghilain@erasme.ulb.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Peeters, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Peggy De Clercq, Study Coordinator</last_name>
      <phone>+32 3 821 53 07</phone>
      <email>peggy.declercq@uza.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Tam, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Malka, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Amal Nacif, Study Coordinator</last_name>
      <phone>+33142116153</phone>
      <email>amal.nacif@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Waidmann, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Studienambulanz Medizinische Klinik 1</last_name>
      <phone>+49 69 6301 87769</phone>
      <email>csc.medklinik1@kgu.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Wege, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>University Medical Center Hamburg-Eppendorf</last_name>
      <phone>+49 40 7410 57981</phone>
      <email>hcc@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Universitätsklinikum des Saarlandes Klinik für Innere Medizin II (Studienbüro)</last_name>
      <phone>+49 684116 15288</phone>
    </contact>
    <contact_backup>
      <last_name>OR</last_name>
      <phone>+49 684116 15289</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D08 NHY1</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maeve Lowery, PI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sant'Orsola-Malpighi Hospital, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Brandi, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Marzia Deserti, Study Coordinator</last_name>
      <email>marzia.deserti2@unibo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Mazzaferro, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Emanuela Mazzella, Study Coordinator</last_name>
      <phone>+39 02 23902544</phone>
      <email>emanuela.mazzella@istitutotumori.mi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto - IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Masi, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Cenar Ahmed, Study Coordinator</last_name>
      <phone>+39 050 99 3841</phone>
      <email>ahmedcenar@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Personeni, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Simona Sala, Study Coordinator</last_name>
      <email>simona.sala@humanitas.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-Youn Oh, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Ja Eun Lee, Study Coordinator</last_name>
      <email>zzarone111@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Oh Park, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Moon Sun Jung, Study Coordinator</last_name>
      <email>moonsun1.jung@samsung.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>6591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ah Lee, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Hyunjoo An, Study Coordinator</last_name>
      <email>superexon@daum.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebrón University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Macarulla, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Marta Beltran, Study Coordinator</last_name>
      <email>mbeltran@vhio.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G120YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Evans, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Jill Graham, Research Nurse</last_name>
      <email>Jill.graham@ggc.scot.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cunningham, PI</last_name>
    </contact>
    <contact_backup>
      <last_name>Linda Kirkwood, Study Coordinator</last_name>
      <phone>+44 208 661 3637</phone>
      <email>linda.kirkwood@rmh.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iCCA</keyword>
  <keyword>intrahepatic cholangiocarcinoma</keyword>
  <keyword>FGFR2 gene fusion or FGFR2 gene mutation or amplification</keyword>
  <keyword>biliary cancer</keyword>
  <keyword>bile duct cancer</keyword>
  <keyword>FGFR2 gene rearrangement</keyword>
  <keyword>liver cancer</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>combined hepatocellular and cholangiocarcinoma</keyword>
  <keyword>cHCC-CCA</keyword>
  <keyword>derazantinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

